Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (70)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chiurazzi, P.
Right arrow Articles by Neri, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiurazzi, P.
Right arrow Articles by Neri, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 7, 109-113, Copyright © 1998 by Oxford University Press

ARTICLES

In vitro reactivation of the FMR1 gene involved in fragile X syndrome

P Chiurazzi, MG Pomponi, R Willemsen, BA Oostra and G Neri
Istituto di Genetica Medica, Universita Cattolica, and Centro Ricerche per la Disabilita Mentale e Motoria, Associazione Anni Verdi, Largo F. Vito 1, 00168 Rome, Italy.

Fragile X syndrome is the most frequent cause of heritable mental retardation. Most patients have a mutation in the 5' untranslated region of the FMR1 gene, consisting of the amplification of a polymorphic (CGG)nrepeat sequence, and cytogenetically express the folate-sensitive fragile site FRAXA in Xq27.3. Fragile X patients harbour an expanded sequence with >200 CGG repeats (full mutation), accompanied by methylation of most cytosines of the sequence itself and of the upstream CpG island. This abnormal hypermethylation of the promoter suppresses gene transcription, resulting in the absence of the FMR1 protein. Rare individuals of normal intelligence were shown to carry a completely or partially unmethylated full mutation and to express the FMR1 protein. Given this observation and knowing that the open reading frame of the mutated FMR1 gene is intact, we decided to investigate whether its activity could be restored in vitro by inducing DNA demethylation with 5-azadeoxycytidine (5-azadC) in fragile X patients' lymphoblastoid cells. We report that treatment with 5-azadC causes reactivation of fully mutated FMR1 genes with 300-800 repeats, as shown by the restoration of specific mRNA and protein production. This effect correlates with the extent of promoter demethylation, determined by restriction analysis with methylation-sensitive enzymes. These results confirm the critical role of FMR1 promoter hypermethylation in the pathogenesis of the fragile X syndrome, provide an additional explanation for the normal IQ of the rare males with unmethylated full mutations and pave the way to future attempts at pharmacologically restoring mutant FMR1 gene activity in vivo.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
D. Kumari and K. Usdin
Chromatin Remodeling in the Noncoding Repeat Expansion Diseases
J. Biol. Chem., March 20, 2009; 284(12): 7413 - 7417.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
K. T. Smith, R. D. Nicholls, and D. Reines
The gene encoding the fragile X RNA-binding protein is controlled by nuclear respiratory factor 2 and the CREB family of transcription factors
Nucleic Acids Res., February 25, 2006; 34(4): 1205 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. J. Mulvihill, K. N. Edamura, K. A. Hagerman, C. E. Pearson, and Y.-H. Wang
Effect of CAT or AGG Interruptions and CpG Methylation on Nucleosome Assembly upon Trinucleotide Repeats on Spinocerebellar Ataxia, Type 1 and Fragile X Syndrome
J. Biol. Chem., February 11, 2005; 280(6): 4498 - 4503.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
R. Pietrobono, E. Tabolacci, F. Zalfa, I. Zito, A. Terracciano, U. Moscato, C. Bagni, B. Oostra, P. Chiurazzi, and G. Neri
Molecular dissection of the events leading to inactivation of the FMR1 gene
Hum. Mol. Genet., January 15, 2005; 14(2): 267 - 277.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
K. T. Smith, B. Coffee, and D. Reines
Occupancy and synergistic activation of the FMR1 promoter by Nrf-1 and Sp1 in vivo
Hum. Mol. Genet., August 1, 2004; 13(15): 1611 - 1621.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
P. Weisman-Shomer, E. Cohen, I. Hershco, S. Khateb, O. Wolfovitz-Barchad, L. H. Hurley, and M. Fry
The cationic porphyrin TMPyP4 destabilizes the tetraplex form of the fragile X syndrome expanded sequence d(CGG)n
Nucleic Acids Res., July 15, 2003; 31(14): 3963 - 3970.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
E Pascale, E Battiloro, G C. Reale, R Pietrobono, M G Pomponi, P Chiurazzi, R Nicolai, M Calvani, G Neri, and E D'Ambrosio
Modulation of methylation in the FMR1 promoter region after long term treatment with L-carnitine and acetyl-L-carnitine
J. Med. Genet., June 1, 2003; 40(6): e76 - 76.
[Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
R. Pietrobono, M. G. Pomponi, E. Tabolacci, B. Oostra, P. Chiurazzi, and G. Neri
Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine
Nucleic Acids Res., July 15, 2002; 30(14): 3278 - 3285.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. B. Fulmer-Smentek and U. Francke
Association of acetylated histones with paternally expressed genes in the Prader-Willi deletion region
Hum. Mol. Genet., March 1, 2001; 10(6): 645 - 652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Plumb, G. Strathdee, J. Sludden, S. B. Kaye, and R. Brown
Reversal of Drug Resistance in Human Tumor Xenografts by 2'-Deoxy-5-azacytidine-induced Demethylation of the hMLH1 Gene Promoter
Cancer Res., November 1, 2000; 60(21): 6039 - 6044.
[Abstract] [Full Text]

Home page
 Hum Mol GenetHome page
P. Jin and S. T. Warren
Understanding the molecular basis of fragile X syndrome
Hum. Mol. Genet., April 1, 2000; 9(6): 901 - 908.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Muller-Hartmann, H. Deissler, F. Naumann, B. Schmitz, J. Schroer, and W. Doerfler
The Human 20-kDa 5'-(CGG)n-3'-binding Protein Is Targeted to the Nucleus and Affects the Activity of the FMR1 Promoter
J. Biol. Chem., February 25, 2000; 275(9): 6447 - 6452.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
W. J. MUIR
Genetics advances and learning disability
The British Journal of Psychiatry, January 1, 2000; 176(1): 12 - 18.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
A. Hmadcha, F. J. Bedoya, F. Sobrino, and E. Pintado
Methylation-Dependent Gene Silencing Induced by Interleukin 1{beta} via Nitric Oxide Production
J. Exp. Med., December 6, 1999; 190(11): 1595 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. S. Hansen, T. K. Canfield, A. M. Stanek, E. A. Keitges, and S. M. Gartler
Reactivation of XIST in normal fibroblasts and a somatic cell hybrid: Abnormal localization of XIST RNA in hybrid cells
PNAS, April 28, 1998; 95(9): 5133 - 5138.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Kumari and K. Usdin
Interaction of the Transcription Factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 Promoter. IMPLICATIONS FOR FRAGILE X MENTAL RETARDATION SYNDROME
J. Biol. Chem., February 2, 2001; 276(6): 4357 - 4364.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.